CRP and chronic obstructive pulmonary disease: A 28 days trial of p38MAPK inhibitor SB681323 in patients with moderate stable COPD reduced sputum neutrophils and plasma fibrinogen with improvement in forced vital capacity.242 The patients with moderate to severe COPD receiving p38MAPK inhibitor PH797804 for 6 week decreased serum CRP levels, and induced a significant increase of FEV1 and a concomitant improvement in dyspnoea score.243 Each subtype of p38MAPK has unique functions due to differential expression across tissue types and different regulatory kinases and downstream genes, hence their targeting comes with adverse effects.